C4 Therapeutics, Inc.
CCCC· Nasdaq
Released Feb 22, 2024, before the open
10-K filed Feb 22, 2024, 53 days after period end · 0001628280-24-006144
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|
| Revenue | $3.26M | — |
| Net Income | -$34.75M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
C4 Therapeutics, Inc. · CIK 1662579 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 22, 2024 · 53 d after period end
+21.4% from the close of Feb 21, 2024 to the close of Feb 22, 2024, the first after the release.